Bristol-Myers's $74 Billion Celgene Splurge Just Got Riskier

Bookmark
(Bloomberg Opinion) -- Bristol-Myers Squibb Co. really wants to get its $74 billion deal for Celgene Inc. done. 
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.